The demand for GLP-1 agonists such as Ozempic, Zepbound, and other medications continues to rise, despite the increasing restrictions on insurance coverage for these drugs. According to GoodRx’s analyses of data from Managed Markets Insight and Technology, insurance coverage for Ozempic decreased by 22% from 2024 to 2025, leaving an additional 1.1 million people without coverage for this popular medication. Similarly, the number of people without insurance coverage for Zepbound, another GLP-1 agonist, increased by 14%, affecting around 4.9 million individuals.
As the popularity of these medications continues to grow, fueled by their potential for rapid weight loss, the issue of insurance coverage becomes more complex. While Zepbound, Wegovy, and Saxenda are FDA-approved for weight loss, medications like Ozempic, Mounjaro, and Victoza are primarily indicated for the treatment of Type 2 diabetes. However, the trend of using these drugs for weight loss is evident, leading to their increased demand.
Despite their effectiveness, GLP-1 agonists are not without potential drawbacks, including side effects like “Ozempic butt” and “Wegovy finger,” as well as more serious complications such as ileus. Additionally, the long-term effects of these medications are still unknown, as studies have not extended over decades.
The cost of GLP-1 agonists is another significant concern, with medications like Ozempic and Zepbound carrying hefty price tags. The list price for an Ozempic injection pen is nearly $1,000, while Zepbound costs over $1,000 per fill. Given that these medications are typically taken weekly, the monthly costs can quickly add up to over $1,300. Therefore, having health insurance coverage to offset these expenses is crucial for many individuals.
Understanding insurance coverage for GLP-1 agonists can be challenging, as policies vary in terms of coverage restrictions. Insurance companies may require prior authorization or impose other requirements before covering these medications, making access more difficult for some individuals. The changing landscape of insurance coverage for medications like Victoza, Saxenda, and Wegovy further complicates the situation, with some experiencing decreases in coverage while others see slight improvements.
Looking ahead, insurance coverage for GLP-1 agonists will likely remain a growing concern, especially as more medications enter the market. While the potential for cost savings in other areas of healthcare may exist with weight loss from these drugs, insurance companies may prioritize short-term profits over long-term benefits. As prices for GLP-1 agonists fluctuate and more generic options become available, the issue of insurance coverage will continue to evolve. Individuals interested in these medications are advised to check with their insurance plans to understand their coverage options and potential costs.
